Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$

Name of entity

Growthpoint Properties Australia Limited/Growthpoint Properties Australia Trust (GOZ)

ABN

ABN 33 124 093 901/ARSN 120 121 002

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of *securities issued or to be issued

- Ordinary shares and units (Stapled Securities)
- Unlisted performance rights (Performance Rights)

⁺ See chapter 19 for defined terms.

- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 35,486 Stapled Securities
- 35,486 FY 19 transitional long term incentive (LTI) Performance Rights (tranche 2)
- 587,855 FY20 forward looking LTI Performance Rights
- 51, 652 FY19 deferred short term incentive (**STI**) Performance Rights-(tranche 1)
- 51,650 FY19 deferred STI Performance Rights (tranche 2)
- 42,847 FY20 deferred STI Performance Rights (tranche 1)
- 42,848 FY20 deferred STI Performance Rights (tranche 2)
- **Principal** of the 3 terms +securities (e.g. if options, exercise price and expiry date; if paid partly +securities, amount outstanding and due dates for payment; if +convertible securities. the conversion price and dates for conversion)

Stapled Securities have the same terms as existing fully paid ordinary stapled securities.

Performance Rights granted entitle eligible employees to receive fully paid ordinary stapled securities on the relevant vesting date for nil consideration. In addition, vesting of the FY20 forward looking LTI Performance Rights and the FY 20 deferred STI Performance Rights (tranches 1 and 2) are subject to satisfaction of the applicable performance conditions.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

fully paid ordinary stapled securities.

Stapled Securities rank equally with existing

Stapled securities to be issued on vesting of the Performance Rights will rank equally with all existing fully paid ordinary stapled securities on issue.

5 Issue price or consideration

il.			

⁺ See chapter 19 for defined terms.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Following securityholder approval at the 2019 Annual General Meeting (AGM), under the Growthpoint Properties Australia Employee Incentive Plan (Plan), the Managing Director was:

- issued the Stapled Securities (tranche 1 of the FY19 transitional employee LTI plan); and
- granted the FY19 transitional LTI Performance Rights (tranche 2).

The FY20 forward looking LTI Performance Rights were granted to eligible employees under the Plan (including the Managing Director following securityholder approval at the 2019 AGM).

The FY19 deferred STI Performance Rights (tranches 1 and 2) were granted to executive key management personnel (KMP) under the Plan as part of their FY19 deferred STI remuneration, as disclosed in the FY19 Remuneration Report (including to the Managing Director following securityholder approval at the 2019 AGM).

The FY20 deferred STI Performance Rights (tranches 1 and 2) were granted to executive KMP (excluding the Managing Director) under the Plan as the deferred component of their FY20 remuneration, which are subject to testing against applicable performance conditions. To the extent that the conditions are not met, a proportion of these Performance Rights will lapse. Subject to approval by securityholders at the 2020 AGM, it is proposed that the Managing Director will be granted with FY20 deferred STI Performance Rights (tranches 1 and 2) under the Plan as the deferred component of his FY20 remuneration.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

No

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval	N/A
	under rule 7.1A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A
7	⁺ Issue dates	12 December 2019
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	12 December 2019

⁺ See chapter 19 for defined terms.

8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
771,780,009	fully paid ordinary stapled securities

Number	+(' acc	
Number	†Class	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	376,822	Performance Rights granted under the Plan (FY19 forward-looking employee LTI plan). 11,383 Performance Rights have lapsed since the last Appendix 3B lodged on 14 October 2019.
		86,460	Performance Rights granted under the Plan (FY19 transitional employee LTI plan - tranche 2). 2609 Performance Rights have lapsed since the last Appendix 3B lodged on 14 October 2019.
		587,855	Performance Rights granted under the Plan (FY20 forward-looking employee LTI plan).
		51, 652	FY 19 deferred STI rights (tranche 1) granted under the Plan.
		51,650	FY 19 deferred STI rights (tranche 2) granted under the Plan.
		42,847	FY 20 deferred STI rights (tranche 1) granted under the Plan.
		42,848	FY 20 deferred STI rights (tranche 2) granted under the Plan.

⁺ See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Stapled Securities have the same dividend rights as existing fully paid ordinary stapled securities on issue.

LTI Performance Rights are not entitled to dividend rights until they vest into fully paid ordinary stapled securities.

The FY19 deferred STI Performance Rights are entitled to receive distributions paid by GOZ equivalent to the distribution that would have been received if holding a fully paid ordinary stapled security. Such payment is to be made in cash on the same date such distribution is payable. The FY20 deferred STI Performance Rights that are on foot after testing against applicable performance conditions will be eligible to distributions on the same basis.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
	of commission	
22	Names of any brokers to the	N/A
	issue	
23	Fee or commission payable to the	N/A
	broker to the issue	
24	Amount of any handling fee	N/A
	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	Security Horacia	
25	If the issue is contingent on	N/A
	security holders' approval, the date of the meeting	
	date of the meeting	
26	Date entitlement and acceptance	N/A
	form and offer documents will be sent to persons entitled	
	sent to persons entitled	
27	If the entity has issued options,	N/A
	and the terms entitle option holders to participate on	
	holders to participate on exercise, the date on which	
	notices will be sent to option	
	holders	
28	Date rights trading will begin (if	N/A
	applicable)	·
	Data dahta tarihara di an 1 ()	DY/A
29	Date rights trading will end (if applicable)	N/A
	approximately	
30	How do security holders sell	N/A
,	their entitlements in full through	,
	a broker?	
31	How do security holders sell <i>part</i>	N/A
<i>)</i> -	of their entitlements through a	- '/
	broker and accept for the	
	balance?	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
		uotation of securitie	S oplying for quotation of securities
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part	1 (Stapled Securities only)
(b)		•	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitio	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new	v class of securities
Tick to łocume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			r securities, a distribution schedule of the additional amber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

⁺ See chapter 19 for defined terms.

38	Number of *securities for which		
	⁺ quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	⁺ Class

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 12 December 2019

(Company secretary)

Print name: Jacqueline Jovanovski

⁺ See chapter 19 for defined terms.